Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis
Authors' conclusion
SSA impaired the insulin, glucagon, and incretin hormone secretions. Co-treatment with PEG seemed to counteract the somatostatinergic inhibition of the glucagon and insulin response to OGTT. We speculate that PEG may exert its action through GH-receptors on pancreatic δ-cells.
Study context
- Population
- Surgically treated, non-diabetic patients with acromegaly and healthy controls; Oral glucose tolerance test (OGTT) and isoglycaemic IV glucose infusion23 patients · 12 controls
- Participants
- 15 / 4 / 11 / 12
- Comparison
- Acromegaly treatment regimens vs healthy controls
- SSAn = 15
- SSA + Pegvisomant (PEG)n = 4
- SSA ÷ PEGn = 11reference
- Healthy controlsn = 12reference
- Outcome
- Hormone responses to OGTT by treatment regimen
Methodological detailsexplorative, single-centre
- Explorative
- Single-centre
Main finding
As reported in the abstract
- SSA: P = 0.001
- SSA: P > 0.3
Further findings
| Outcome | SSA + PEG | SSA ÷ PEG | P value |
|---|---|---|---|
| Insulin AUCSSA + PEG vs SSA ÷ PEG · increased with SSA + PEG | mean 49 (SE 8.3) nmol/l*min | mean 25 (SE 3.4) | P = 0.007 |
| Glucagon AUCSSA + PEG vs SSA ÷ PEG · increased with SSA + PEG | mean 823 (SE 194) pmol/l*min | mean 332 (SE 69) | P = 0.009 |
| GLP-1 secretionSSA + PEG vs SSA ÷ PEG · numerically increased with PEG | 3088 (SE 366) pmol/l*min | 2401 (SE 239) | P = 0.3 |
GLP-1 secretion
- GIP secretion remained significantly impaired with PEG
Radiotherapy and hydrocortisone substitution
- No difference with/without radiotherapy nor with/without hydrocortisone substitution
Original publication
Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis. Pituitary. Published 6 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →